HSPGs in leverbiopten in mensen met of zonder suikerziekte.
Recruiting
- Conditions
- Type 2 diabetes mellitus, NASH, dyslipidemiaDiabetes mellitus type 2
- Registration Number
- NL-OMON26779
- Lead Sponsor
- Academic Medical Centre Amsterdam
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 8
Inclusion Criteria
Patients with DM:
1. Caucasian males or females;
Exclusion Criteria
1. Use of lipid lowering therapy (Modalim), hormone therapy or other medication which influences the lipid metabolism during the past 6 weeks;
2. Active malignancy (not applicable to hemihepatectomy patients);
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HSPGs expression in liver tissue, measured by qPCR and western blot, in insulin resistant NASH versus non-insulin resistant NASH and controls.
- Secondary Outcome Measures
Name Time Method 1. Association between hepatic HSPGs expression en triglyceride-rich lipoproteins in non-fasting lipid samples;<br /><br>2. Association between hepatic HSPGs expression and HOMA index.